|
1
|
Rini BI, Campbell SC and Escudier B: Renal
cell carcinoma. Lancet. 73:1119–1132. 2009. View Article : Google Scholar
|
|
2
|
Motzer RJ, Bander NH and Nanus DM:
Renal-cell carcinoma. N Engl J Med. 335:865–875. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Carmeliet P and Jain RK: Angiogenesis in
cancer and other diseases. Nature. 407:249–257. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Qian CN, Huang D, Wondergem B and Teh BT:
Complexity of tumor vasculature in clear cell renal cell carcinoma.
Cancer. 115:(Suppl 10). S2282–S2289. 2009. View Article : Google Scholar
|
|
5
|
Xu L, Tong R, Cochran DM and Jain RK:
Blocking platelet-derived growth factor-D/platelet-derived growth
factor receptor beta signaling inhibits human renal cell carcinoma
progression in an orthotopic mouse model. Cancer Res. 65:5711–5719.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sulzbacher I, Birner P, Träxler M,
Marberger M and Haitel A: Expression of platelet-derived growth
factor-alpha alpha receptor is associated with tumor progression in
clear cell renal cell carcinoma. Am J Clin Pathol. 120:107–112.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dorević G, Matusan-Ilijas K, Babarović E,
Hadzisejdić I, Grahovac M, Grahovac B and Jonjić N: Hypoxia
inducible factor-1α correlates with vascular endothelial growth
factor A and C indicating worse prognosis in clear cell renal cell
carcinoma. J Exp Clin Cancer Res. 28:402009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Watanabe K, Hasegawa Y, Yamashita H,
Shimizu K, Ding Y, Abe M, Ohta H, Imagawa K, Hojo K, Maki H, et al:
Vasohibin as an endothelium-derived negative feedback regulator of
angiogenesis. J Clin Invest. 114:898–907. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sonoda H, Ohta H, Watanabe K, Yamashita H,
Kimura H and Sato Y: Multiple processing forms and their biological
activities of a novel angiogenesis inhibitor vasohibin. Biochem
Biophys Res Commun. 342:640–646. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nasu T, Maeshima Y, Kinomura M,
Hirokoshi-Kawahara K, Tanabe K, Sugiyama H, Sonoda H, Sato Y and
Makino H: Vasohibin-1, a negative feedback regulator of
angiogenesis, ameliorates renal alterations in a mouse model of
diabetic nephropathy. Diabetes. 58:2365–2375. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shen J, Yang X, Xiao WH, Hackett SF, Sato
Y and Campochiaro PA: Vasohibin is up-regulated by VEGF in the
retina and suppresses VEGF receptor 2 and retinal
neovascularization. FASEB J. 20:723–725. 2006.PubMed/NCBI
|
|
12
|
Tamaki K, Moriya T, Sato Y, Ishida T,
Maruo Y, Yoshinaga K, Ohuchi N and Sasano H: Vasohibin-1 in human
breast carcinoma: A potential negative feedback regulator of
angiogenesis. Cancer Sci. 100:88–94. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yoshinaga K, Ito K, Moriya T, Nagase S,
Takano T, Niikura H, Yaegashi N and Sato Y: Expression of vasohibin
as a novel endothelium-derived angiogenesis inhibitor in
endometrial cancer. Cancer Sci. 99:914–919. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yoshinaga K, Ito K, Moriya T, Nagase S,
Takano T, Niikura H, Sasano H, Yaegashi N and Sato Y: Roles of
intrinsic angiogenesis inhibitor, vasohibin, in cervical
carcinomas. Cancer Sci. 102:446–451. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hosaka T, Kimura H, Heishi T, Suzuki Y,
Miyashita H, Ohta H, Sonoda H, Moriya T, Suzuki S, Kondo T, et al:
Vasohibin-1 expression in endothelium of tumor blood vessels
regulates angiogenesis. Am J Pathol. 175:430–439. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang Q, Tian X, Zhang C and Wang Q:
Upregulation of vasohibin-1 expression with angiogenesis and poor
prognosis of hepatocellular carcinoma after curative surgery. Med
Oncol. 29:2727–2736. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shen Z, Kauttu T, Seppänen H, Vainionpää
S, Ye Y, Wang S, Mustonen H and Puolakkainen P: Vasohibin-1 and
vasohibin-2 expression in gastric cancer cells and TAMs. Med Oncol.
29:2718–2726. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang T, Yu TT, Zhang DM, Hou XM, Liu XJ,
Zhao D and Shan L: Vasohibin-1 expression detected by
immunohistochemistry correlates with prognosis in non-small cell
lung cancer. Med Oncol. 31:9632014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu S, Han B, Zhang Q, Dou J, Wang F, Lin
W, Sun Y and Peng G: Vasohibin-1 suppresses colon cancer.
Oncotarget. 6:7880–7898. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Takahashi Y, Saga Y, Koyanagi T, Takei Y,
Machida S, Taneichi A, Mizukami H, Sato Y, Matsubara S and Fujiwara
H: The angiogenesis regulator vasohibin-1 inhibits ovarian cancer
growth and peritoneal dissemination and prolongs host survival. Int
J Oncol. 47:2057–2063. 2015.PubMed/NCBI
|
|
21
|
Takahashi Y, Saga Y, Koyanagi T, Takei Y,
Machida S, Taneichi A, Mizukami H, Sato Y, Matsubara S and Fujiwara
H: Vasohibin-1 expression inhibits advancement of ovarian cancer
producing various angiogenic factors. Cancer Sci. 107:629–637.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shen Z, Yan Y, Ye C, Wang B, Jiang K, Ye
Y, Mustonen H, Puolakkainen P and Wang S: The effect of Vasohibin-1
expression and tumor-associated macrophages on the angiogenesis in
vitro and in vivo. Tumour Biol. 37:7267–7276. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao G, Yang Y, Tang Y, Han R and Sun Y:
Reduced expression of vasohibin-1 is associated with
clinicopathological features in renal cell carcinoma. Med Oncol.
29:3325–3334. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Folkman J: Tumor angiogenesis: Therapeutic
implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Folkman J: Role of angiogenesis in tumor
growth and metastasis. Semin Oncol. 29:(Suppl 16). S15–S18. 2002.
View Article : Google Scholar
|
|
26
|
Mancilla-Jimenez R, Stanley RJ and Blath
RA: Papillary renal cell carcinoma: A clinical, radiologic, and
pathologic study of 34 cases. Cancer. 38:2469–2480. 1976.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nimmagadda S, Geetha-Loganathan P, Pröls
F, Scaal M, Christ B and Huang R: Expression pattern of
Vasohibin during chick development. Dev Dyn. 236:1358–1362.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Naito H, Kidoya H, Sato Y and Takakura N:
Induction and expression of anti-angiogenic vasohibins in the
hematopoietic stem/progenitor cell population. J Biochem.
145:653–659. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Vitale MG and Cartenì G: Clinical
management of metastatic kidney cancer: The role of new molecular
drugs. Future Oncol. 12:83–93. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Miyashita H, Suzuki H, Ohkuchi A and Sato
Y: Mutual balance between vasohibin-1 and soluble VEGFR-1 in
endothelial cells. Pharmaceuticals. 4:782–793. 2011. View Article : Google Scholar :
|
|
31
|
Heishi T, Hosaka T, Suzuki Y, Miyashita H,
Oike Y, Takahashi T, Nakamura T, Arioka S, Mitsuda Y, Takakura T,
et al: Endogenous angiogenesis inhibitor vasohibin1 exhibits
broad-spectrum antilymphangiogenic activity and suppresses lymph
node metastasis. Am J Pathol. 176:1950–1958. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li D, Zhou K, Wang S, Shi Z and Yang Z:
Recombinant adenovirus encoding vasohibin prevents tumor
angiogenesis and inhibits tumor growth. Cancer Sci. 101:448–452.
2010. View Article : Google Scholar : PubMed/NCBI
|
